Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · see citing works

Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease

Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786 · see citing works

Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933 · see citing works

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668 · see citing works

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · see citing works

Amyloid β-peptide is produced by cultured cells during normal metabolism

Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921 · see citing works

Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · see citing works

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525 · see citing works

Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions

William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107 · see citing works

Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein

Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 827 · see citing works

Alzheimer's Disease: A Central Role for Amyloid

Selkoe, D. J. (1994) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199409000-00003 · Cited by 752 · see citing works

Improved discrimination of AD patients using β-amyloid _(1-42) and tau levels in CSF

Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain

Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676 · see citing works

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., & Kontula, K. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331902 · Cited by 493 · see citing works

High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype

Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442 · see citing works

Evidence that Aβ42 is the real culprit in alzheimer's disease

Younkin, S. G. (1995) · Annals of Neurology · doi:10.1002/ana.410370303 · Cited by 331 · see citing works

Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 219 · see citing works

Characterization of Apolipoprotein J-Alzheimer's Aβ Interaction

Matsubara, E., Frangione, B., & Ghiso, J. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7563 · Cited by 195 · see citing works

Amyloid β protein in plasma from patients with sporadic Alzheimer's disease

Tamaoka, A., Fukushima, T., Sawamura, N., Ishikawa, K., Oguni, E., Komatsuzaki, Y., & Shoji, S. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00143-8 · Cited by 154 · see citing works

Clinical Correlates of Cortical and Nucleus Basalis Pathology in Alzheimer Dementia

Samuel, W., Terry, R. D., DeTeresa, R. M., Butters, N., & Masliah, E. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540200048015 · Cited by 140 · see citing works

Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease

Tamaoka, A., Sawamura, N., Fukushima, T., Shoji, S., Matsubara, E., Shoji, M., Hirai, S., Furiya, Y., Endoh, R., & Mori, H. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00314-0 · Cited by 139 · see citing works

Cerebrovascular transport of Alzheimer's amyloidβ and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood-brain barrier

Zloković, B. V. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00310-4 · Cited by 138 · see citing works

Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease

Lehtim�ki, T., Pirttil�, T., Mehta, P., Wisniewski, H., Frey, H., & Nikkari, T. (1995) · Human Genetics · doi:10.1007/bf00225071 · Cited by 125 · see citing works

Increased plasma amyloid β protein 1–42 levels in Down syndrome

Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., & Wisniewski, H. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00966-x · Cited by 108 · see citing works

Assessment of Amyloid β Protein in Cerebrospinal Fluid as an Aid in the Diagnosis of Alzheimer's Disease

Southwick, P. C., Yamagata, S. K., Echols, C. L., Higson, G. J., Neynaber, S. A., Parson, R. E., & Munroe, W. A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66010259.x · Cited by 89 · see citing works

Aβ1–40 but not Aβ1–42 levels in cortex correlate with apolipoprotein E ϵ4 allele dosage in sporadic Alzheimer's disease

Ishii, K., Tamaoka, A., Mizusawa, H., Shoji, S.-I., Ohtake, T., Fraser, P. E., Takahashi, H., Tsuji, S., Gearing, M., Mizutani, T., et al. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01363-7 · Cited by 85 · see citing works

Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls

Pirttilä, T., Kim, K. S., Mehta, P. D., Frey, H., & Wı́sniewski, H. M. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90140-6 · Cited by 79 · see citing works

Amyloid β protein 1–42/43 (Aβ 1–42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study

Tamaoka, A., Sawamura, N., Odaka, A., Suzuki, N., Mizusawa, H., Shoji, S., & Mori, H. (1995) · Brain Research · doi:10.1016/0006-8993(95)00162-j · Cited by 72 · see citing works

CSF beta-amyloid, cognition, and APOE genotype in Alzheimer’s disease

Samuels, S., Silverman, J. M., Marin, D. B., Peskind, E. R., Younki, S. G., Greenberg, D. A., Schnur, E., Santoro, J., & Davis, K. L. (1999) · Neurology · doi:10.1212/wnl.52.3.547 · Cited by 67 · see citing works

Neuropathology of Alzheimer's disease

Tomonaga, M. (1989) · Neuroscience Research Supplements · doi:10.1016/0921-8696(89)90516-1 · Cited by 62 · see citing works

Quantification of sub-femtomole amounts of Alzheimer amyloid β peptides

Potempska, A., Mack, K., Mehta, P. D., Kim, K. S., & Miller, D. L. (1999) · Amyloid · doi:10.3109/13506129908993283 · Cited by 35 · see citing works

High molecular weight Alzheimer's disease amyloid peptide immunoreactivity in human serum and CSF is an immunoglobulin G

Pardridge, W. M., Vinters, H. V., Miller, B. L., Tourtellotte, W. W., Eisenberg, J., & Yang, J. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)91312-x · Cited by 28 · see citing works

Antibodies to the β‐amyloid peptide cross‐react with conformational epitopes in human fibrinogen subunits from peripheral blood

Stem, R. A., Trojanowski, J. Q., & Lee, V. M. ‐. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)80760-g · Cited by 23 · see citing works

Autosomal dominant spastic paraplegia linked to chromosome 2p: clinical and genetic studies of a large Japanese pedigree

Matsuura, T., Sasaki, H., Wakisaka, A., et al. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00107-x · Cited by 21 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Alzheimer's disease

Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works

Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial

Baker, L. D., Frank, L. L., Foster-Schubert, K., Green, P. S., Wilkinson, C. W., McTiernan, A., Plymate, S. R., Fishel, M. A., Watson, G. S., Cholerton, B. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.307 · Cited by 1,171 · see citing works

Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers

Townsend, M., Shankar, G. M., Mehta, T., Walsh, D. M., & Selkoe, D. J. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.103754 · Cited by 619 · see citing works

Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease

Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572 · see citing works

Current state of Alzheimer’s fluid biomarkers

Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works

Amyloid biomarkers in Alzheimer's disease

Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · see citing works

Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk

Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434 · see citing works

Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis

Herzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., Danner, S., Abramowski, D., Stürchler-Pierrat, C., Bürki, K., et al. (2004) · Nature Neuroscience · doi:10.1038/nn1302 · Cited by 391 · see citing works

Cerebrospinal Fluid Tau and β-Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses?

Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357 · see citing works

Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests

Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247 · see citing works

Hypometabolism and Altered Cerebrospinal Fluid Markers in Normal Apolipoprotein E E4 Carriers with Subjective Memory Complaints

Mosconi, L., De Santi, S., Brys, M., Tsui, W. H., Pirraglia, E., Glodzik-Sobanska, L., Rich, K. E., Switalski, R., Mehta, P. D., Pratico, D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.030 · Cited by 238 · see citing works

Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing

Brown, B. M., Peiffer, J. J., Taddei, K., Lui, J. K., Laws, S. M., Gupta, V. B., Taddei, T., Ward, V. K., Rodrigues, M. A., Burnham, S., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.107 · Cited by 235 · see citing works

The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease

Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J.-F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508781200 · Cited by 233 · see citing works

Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease

Schupf, N., Tang, M. X., Fukuyama, H., Manly, J., Andrews, H., Mehta, P., Ravetch, J., & Mayeux, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805902105 · Cited by 225 · see citing works

Biomarkers for the Early Detection and Progression of Alzheimer's Disease

Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224 · see citing works

Fluid Biomarkers in Alzheimer Disease

Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208 · see citing works

Determination of β-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry

Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., & Blennow, K. (2006) · Journal of Proteome Research · doi:10.1021/pr050475v · Cited by 206 · see citing works

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190 · see citing works

Blood-Based Biomarkers of Alzheimer's Disease: Challenging but Feasible

Thambisetty, M., & Lovestone, S. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.84 · Cited by 182 · see citing works

Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes

Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Cao, P., Kolody, H., Vedders, L., Kolb, W. P., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.043 · Cited by 175 · see citing works

Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease?

Sun, X., Steffens, D. C., Au, R., Folstein, M., Summergrad, P., Yee, J., Rosenberg, I., Mwamburi, D. M., & Qiu, W. Q. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.5.542 · Cited by 174 · see citing works

Nonfibrillar diffuse amyloid deposition due to a gamma42-secretase site mutation points to an essential role for N-truncated Abeta42 in Alzheimer's disease

Kumar-Singh, S. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2589 · Cited by 158 · see citing works

Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention

Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149 · see citing works

CSF biomarkers for mild cognitive impairment

Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151 · see citing works

Therapeutic Potential of γ -Secretase Inhibitors and Modulators

Imbimbo, B. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783334015 · Cited by 143 · see citing works

Biochemically-defined pools of amyloid-β in sporadic Alzheimer’s disease: correlation with amyloid PET

Roberts, B. R., Lind, M., Wagen, A. Z., Rembach, A., Frugier, T., Li, Q.-X., Ryan, T. M., McLean, C. A., Doecke, J. D., Rowe, C. C., et al. (2017) · Brain · doi:10.1093/brain/awx057 · Cited by 143 · see citing works

<i>APOE</i> ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42

Prince, J. A., Zetterberg, H., Andreasen, N., Marcusson, J., & Blennow, K. (2004) · Neurology · doi:10.1212/01.wnl.0000128088.08695.05 · Cited by 128 · see citing works

Circulating Biomarkers of Cognitive Decline and Dementia

Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120 · see citing works

Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice

Westmark, C. J., Westmark, P. R., O'Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., Abozeid, S. H., Stein, K. M., Stodola, L. A., Tranfaglia, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026549 · Cited by 110 · see citing works

Effects of folic acid supplementation on cognitive function and Aβ-related biomarkers in mild cognitive impairment: a randomized controlled trial

Ma, F., Li, Q., Zhou, X., Zhao, J., Song, A., Li, W., Liu, H., Xu, W., & Huang, G. (2019) · European Journal of Nutrition · doi:10.1007/s00394-017-1598-5 · Cited by 90 · see citing works

Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation

Kauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Goate, A. M. (2007) · Annals of Neurology · doi:10.1002/ana.21099 · Cited by 84 · see citing works

Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?

Mahgoub, N., & Alexopoulos, G. S. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.12.003 · Cited by 81 · see citing works

Physiological Roles of β-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology

Cai, W., Li, L., Sang, S., Pan, X., & Zhong, C. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-022-00985-9 · Cited by 83 · see citing works

Quantitative analysis of co-oligomer formation by amyloid-beta peptide isoforms.

Iljina, M., Garcia, G. A., Dear, A. J., Flint, J., Narayan, P., Michaels, T. C. T., Dobson, C. M., Frenkel, D., Knowles, T. P. J., & Klenerman, D. (2016) · Scientific Reports · doi:10.1038/srep28658 · Cited by 68 · see citing works

The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: Correlation with cognitive and functional decline

Öztürk, C., Özge, A., Yalın, O. Ö., Yılmaz, &. A., Delialioglu, N., Yıldız, Ç., Tesdelen, B., & Kudiaki, C. (2007) · Behavioural Neurology · doi:10.1155/2007/432190 · Cited by 46 · see citing works

Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's

Mosconi, L., Glodzik, L., Mistur, R., McHugh, P., Rich, K. E., Javier, E., Williams, S., Pirraglia, E., De Santi, S., Mehta, P. D., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.011 · Cited by 46 · see citing works

Magnetic resonance and PET studies in the early diagnosis of Alzheimer’s disease

Mosconi, L., De Santi, S., Rusinek, H., Convit, A., & de Leon, M. J. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.5.831 · Cited by 46 · see citing works

Progress and challenges in the diagnosis of dementia: a critical review

Paraskevaidi, M., Martin-Hirsch, P. L., & Martin, F. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00007 · Cited by 31 · see citing works

Alzheimer's disease biomarkers: correspondence between human studies and animal models

Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27 · see citing works

Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer’s disease

Hsu, J.-L., Lee, W.-J., Liao, Y.-C., Lirng, J.-F., Wang, S.-J., & Fuh, J.-L. (2017) · Scientific Reports · doi:10.1038/s41598-017-05390-1 · Cited by 18 · see citing works

Cerebrospinal fluid apolipoprotein E is reduced in Alzheimerʼs disease

Blennow, K., Hesse, C., & Fredman, P. (1994) · Neuroreport · doi:10.1097/00001756-199412000-00032 · Cited by 96 · see citing works

The −491A/T polymorphism of the Apolipoprotein E gene is associated with the ApoEϵ4 allele and Alzheimer's Disease

Ahmed, A. R. H., MacGowan, S. H., Culpan, D., Jones, R. W., & Wilcock, G. K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00126-3 · Cited by 24 · see citing works

Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients

Rösler, N., Wichart, I., & Jellinger, K. A. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01514-2 · Cited by 20 · see citing works

Apoptosis in neurones exposed to cerebrospinal fluid from patients with multiple sclerosis or acute polyradiculoneuropathy

Øren, A., White, L. R., & Aasly, J. O. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00496-8 · Cited by 8 · see citing works

Apolipoprotein E in Cerebrospinal Fluid from Patients with Alzheimer's Disease and Other Forms of Dementia Is Reduced but without Any Correlation to the apoE4 Isoform

Landén, M., Hesse, C., Fredman, P., Regland, B., Wallin, A., & Blennow, K. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106892 · Cited by 49 · see citing works